Article

Can FLAIR MRI Show Treatment Efficacy?

Focal gadolinium enhancement may provide clues


 

References

Postcontrast T2-weighted, fluid attenuated inversion recovery (FLAIR) MRI is a noninvasive method for testing in vivo markers of subpial demyelination and could be used to determine efficacy of new treatments aimed at eliminating this inflammation in patients with progressive multiple sclerosis (MS). This is the key finding of brain MRI studies collected from 299 MS patients and 37 age-matched neurologically healthy controls.

Expert raters evaluated radiography images and found:

• Focal gadolinium enhancement was present in the leptomeningeal compartment in 25% of MS cases, compared with 2.7% of controls.

• Enhancement was more frequent in patients with progressive MS compared to relapsing-remitting MS, 33% to 19%.

• Enhancing foci remained generally stable during an evaluation period of up to 5.5 years.

Citation: Absinta M, Vuolo L, Rao A, et al. Gadolinium-based MRI characterization of leptomeningeal inflammation in multiple sclerosis. Neurology. 2015. doi:10.1212/WNL.0000000000001587.

Recommended Reading

CMSC Guidelines: MRI Protocols in Multiple Sclerosis
MDedge Neurology
DECIDE: Daclizumab cuts MS relapse rate by 45%
MDedge Neurology
Experimental MS Drug May Repair Nerve Damage
MDedge Neurology
Can Coffee Reduce the Risk of MS?
MDedge Neurology
What Happens When Patients With MS Stop Taking Their Medication?
MDedge Neurology
Epilepsy Drug May Preserve Eyesight for Patients With MS
MDedge Neurology
Tips for Coping With Multiple Sclerosis
MDedge Neurology
Switch to Oral Fingolimod May Improve MS Outcomes
MDedge Neurology
Conference News Update—Federation of American Societies for Experimental Biology
MDedge Neurology
Robert Fox, MD
MDedge Neurology